Methods of treating cancer by administering anti-GPR49 antibodies

US9220774B2 · kind B2 · utility

Assignee

• Bionomics Limited · AU

Inventors

• Christopher L. Reyes · Adelaide, AU
• Peter Chu · Hawthorne, US
• Xiangyang Tan · Tewksbury, US
• Weixing Yang · Newton, US
• Christilyn Graff · Cambridge, US

Key dates

• Filing date: Oct 31, 2012
• Grant date: Dec 29, 2015
• Expiry date: Oct 31, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described herein are antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies.